News

Development of new CF gene therapy gets $320K NIH grant

Genexys Biomed has been awarded a $320,000 grant to advance the development of a novel gene therapy for cystic fibrosis (CF). The small business innovation research grant was given by the National Heart, Lung, and Blood Institute, a branch of the National Institutes of Health. The “grant is a…

Kalydeco slows CF disease progression over time, study finds

Treatment with Kalydeco (ivacaftor) for almost eight years consistently improved lung function and reduced mortality in people with cystic fibrosis (CF), according to a study looking at several measures of disease progression. The therapy also significantly improved nutritional status, which together with reduced pulmonary exacerbations, hospitalizations, and lung…